Royalty Pharma to pay $1 billion for Roche's SMA drug royalties
Reuters
Published Oct 19, 2023 08:19AM ET
Updated Oct 19, 2023 11:37AM ET
(Reuters) -Royalty Pharma said on Thursday it has purchased additional royalties on Roche and PTC Therapeutics (NASDAQ:PTCT)' oral spinal muscular atrophy (SMA) drug for an upfront payment of $1 billion.
Risdiplam, branded as Evrysdi, was approved by the U.S. Food and Drug Administration in 2020 for the treatment of the disease in adults and children two months and above.
Spinal muscular atrophy, a leading genetic cause of infant deaths, prevents the body from producing a protein necessary for neuromuscular development.
Royalty Pharma said the agreement with PTC (NASDAQ:PTC) increases its ownership of the Evrysdi royalty from 43% to 81%, equating to a royalty of 6.5% to 13%.
The company had in 2020 purchased about 43% of PTC's royalty interest in risdiplam for a one-time payment of $650 million.
PTC said it plans to use the proceeds from the deal to pay back its debt from Blackstone (NYSE:BX) Life Sciences and to fund planned operations.
The agreement "removes a significant financial overhang" and resolves investor concerns related to the company's Blackstone debt obligations, Truist Securities analyst Robyn Karnauskas wrote in a note.
Shares of PTC rose nearly 5% in early trading, while Royalty Pharma was up about 1%.
PTC will also get an option to sell its retained royalties on Evrysdi for up to $500 million at a later date, Royalty Pharma said.
Royalty Pharma expects to fund the transaction with a combination of existing cash and about $350 million from its revolving credit facility.
Evrysdi generated global sales of 1.12 billion Swiss Francs ($1.25 billion) in 2022.
Royalty Pharma buys royalties of future drugs from academic labs and biotechnology companies, which in turn use the cash to fund their research.
($1 = 0.8963 Swiss francs)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.